2026-07-31T12:52:13-05:00 2025-12-31 251637458 LOUIS PLUNG & COMPANY LLP 20 STANWIX ST SUITE 901 PITTSBURGH PA 15222 990 2025-01-01 461909171 COMMUNITY LIVER ALLIANCE COMM 4127424051 100 W STATION SQUARE DRIVE 212 PITTSBURGH PA 15219 SUZANNA MASARTIS CHIEF EXECUTIVE OFFICER 4127424051 2026-07-02 1 LINDSAY ANDREWS P01332714 4122818771 2026-06-25 2025 2025-03-06 01:10:19Z SUZANNA MASARTIS 100 W STATION SQUARE DRIVE 212 PITTSBURGH PA 15219 704849 0 X WWW.COMMUNITYLIVERALLIANCE.ORG X 2013 PA SUPPORTING THE COMMUNITY THROUGH LIVER DISEASE AWARENESS, PREVENTION, EDUCATION AND RESEARCH. 12 12 3 95 0 0 590722 676947 256 2350 21938 19512 15823 -9620 628739 689189 13500 1551 0 0 338945 462387 0 0 166938 221642 334080 574087 798018 54652 -108829 891733 752713 51859 21668 839874 731045 X SUPPORTING THE COMMUNITY THROUGH LIVER DISEASE AWARENESS, PREVENTION, EDUCATION, AND RESEARCH. 0 0 335533 951 EDUCATION - THE FOLLOWING EDUCATION EVENTS WERE HELD DURING 2025.LIVER CANCER CONFERENCE - AT COURSE COMPLETION, ATTENDEES SHOULD BE ABLE TO UNDERSTAND AND HAVE MORE KNOWLEDGE OF THE MOLECULAR CLASSIFICATION OF HEPATOCELLULAR CANCER (HCC) AND THE MULTIDISCIPLINARY APPROACH TO MANAGEMENT OF HCC COMPETENCY, DEFINE THE MECHANISMS THAT LEAD TO THE DEVELOPMENT OF HCC, DISCUSS THE AVAILABLE EVIDENCE-BASED DATA ON PROMISING TREATMENT OPTIONS FOR ADVANCED HCC AND THE ADVANCES IN RESEARCH AND DEVELOPMENT.NASH UPDATE - AT COURSE COMPLETION, ATTENDEES SHOULD HAVE AN INCREASED KNOWLEDGE BASE REGARDING THERAPY FOR NONALCOHOLIC STEATOHEPATITIS (NASH) AND NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) RELATED TO MEDICATION AND ENDOSCOPIC TREATMENTS, AN INCREASED KNOWLEDGE BASE REGARDING MANAGEMENT FOR NASH AND NAFLD RELATED TO NUTRITIONAL AND WEIGHT THERAPIES, AND AN INCREASED KNOWLEDGE BASE REGARDING OPTIONS OF EXTRA-HEPATIC MANIFESTATIONS OF NASH.NASH UPDATE FOR PATIENTS & CAREGIVERS - THE CLA "PATIENT AND CAREGIVER NASH UPDATE" EDUCATIONAL PROGRAM IS A PROVIDER LEAD UPDATE FOR PATIENTS AND CAREGIVERS. THE PROGRAM FORMAT INCLUDES UP TO DATE INFORMATION ABOUT CURRENT TREATMENTS FOR FATTY LIVER, NAFLD, AND NASH, NEW DEVELOPMENTS AND CLINICAL TRIALS, TRANSPLANTATION, NUTRITION, MEDICAID AND MEDICARE UPDATE, RESOURCES, AND A QUESTION & ANSWER SESSION. A POST-PROGRAM EVALUATION IS CONDUCTED TO DETERMINE OTHER AREAS OF EDUCATION NEEDED. IT IS ALSO A CHANCE FOR PATIENTS TO NETWORK.POST AASLD (AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE) - THE GOAL OF THIS PROGRAM IS TO HELP CLINICIANS AND OTHER SERVICE PROVIDERS UNDERSTAND THE LOCAL AND REGIONAL PICTURE OF VIRAL HEPATITIS, MANAGEMENT OF HEPATOCELLULAR CARCINOMA, AUTOIMMUNE AND FATTY LIVER DISEASE IN THE U.S. POPULATION, AND TO OFFER STRATEGIES FORPREVENTION AND CONTROL OF CHRONIC HEPATITIS AND CORRESPONDING CHRONIC LIVER DISEASE.HCV TRAINING - THE GOAL OF THIS PROGRAM IS TO HELP CLINICIANS AND OTHER SERVICE PROVIDERS UNDERSTAND THE LOCAL AND REGIONAL PICTURE OF HEPATITIS C, HCV/HIV COINFECTION, DIAGNOSIS, TREATMENT, MANAGEMENT AND EDUCATION AND TO OFFER STRATEGIES FOR PREVENTION AND CONTROL OF CHRONIC HEPATITIS AND CORRESPONDING CHRONIC LIVER DISEASE.PRIMARY BILIARY CHOLANGITIS (PBC) CAREGIVER EDUCATION - THE CLA "PBC UPDATE" EDUCATIONAL PROGRAM IS A PROVIDERLEAD UPDATE FOR PATIENTS AND CAREGIVERS, AND PROVIDERS ARE ALSO INVITED TO ATTEND. THE PROGRAM FORMAT INCLUDES UPTO DATE INFORMATION ABOUT PBC CURRENT TREATMENTS, NEW DEVELOPMENTS AND CLINICAL TRIALS, TRANSPLANTATION, NUTRITION, MEDICAID AND MEDICARE UPDATE, RESOURCES, AND A QUESTION AND ANSWER SESSION. A POST-PROGRAM EVALUATION ISCONDUCTED TO DETERMINE OTHER AREAS OF EDUCATION NEEDED. IT IS ALSO A CHANCE FOR PATIENTS TO NETWORK AND LEARNABOUT THE CLA LEAD PBC SUPPORT GROUP. 31548 VIRAL HEPATITIS ELIMINATION - ACTIVITIES PERFORMED BY THE ORGANIZATION COMMUNICATING THE PURPOSE AND SERVICES OF THE ORGANIZATION TO ALL POTENTIAL SOURCES OF RESEARCH AND DEVELOPMENT. 100408 ADVOCACY - ACTIVITIES PERFORMED BY THE ORGANIZATION COMMUNICATING THE PURPOSE AND SERVICES OF THE ORGANIZATION TO ALL POTENTIAL SOURCES OF RESEARCH AND DEVELOPMENT. 500 MASH CHALLENGE 600 600 2350 LIVER HERO PROGRAM - THE CLA LIVER HERO FUND WAS ESTABLISHED TO RAISE FUNDS TO SUPPORT THREE IMPORTANT INITIATIVES: (1) LOCAL RESEARCH EACH YEAR $25,000 IS INVESTED THROUGH THE LIVER RESEARCH FUNDING PROGRAM. THE PURPOSE OF THE PROGRAM IS TO PROVIDE FUNDING FOR A LOCAL LIVER RESEARCH PROJECT; (2) PATIENT ASSISTANCE FUND OFTEN TIMES PATIENTS HAVE HARDSHIPS BALANCING LIFE EXPENSES DURING TREATMENT AND TRANSPLANT. THE CLA PATIENT ASSISTANCE PROGRAM PROVIDES A MAXIMUM GRANT OF $250 PER PATIENT, PER YEAR TOWARDS APPROVED EXPENSES; AND (3) CHILDREN'S HOSPITAL OF PITTSBURGH CAMP CHIHOPI YOUTH TRANSPLANT CAMP CAMP CHIHOPI ALLOWS YOUTH TRANSPLANT PATIENTS TO EXPERIENCE TIME AWAY FROM THE HOSPITAL AND THE DAILY DIFFICULTY OF BEING A PATIENT. EACH AUGUST CHILDREN GATHER AT CAMP EMMA KAUFMAN IN WEST VIRGINIA TO ENJOY 4 DAYS OF ACTIVITIES AND FRIENDSHIPS. THE DONATIONS OF THE LIVE HERO FUND ARE 100% DIRECTED TOWARDS THESE INITIATIVES. 1100 600 2350 468589 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 163 0 1 3 1 0 0 0 0 0 0 0 0 0 0 0 0 X 12 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 PA NJ WI CA X X SUZANNA MASARTIS 4127424051 100 W STATION SQUARE DRIVE 212 PITTSBURGH PA 15219 KELLY MARTIN CRNP PRESIDENT 2.00 X X 0 0 0 JENNIFER SKERTICH VICE PRESIDENT 2.00 X X 0 0 0 STACY ACEVEDO RN BSN MSN EDUCATION CHAIR 2.00 X X 0 0 0 TONY CIOTTI TREASURER 2.00 X X 0 0 0 KAPIL CHOPRA MD DIRECTOR 1.00 X 0 0 0 NICK DEGREGORIO MD DIRECTOR 1.00 X 0 0 0 DAVID GELLER MD DIRECTOR 1.00 X 0 0 0 BRUNO MASTROIANNI DIRECTOR 1.00 X 0 0 0 GEORGE MAZARIEGOS MD DIRECTOR 1.00 X 0 0 0 AARON MARTIN DIRECTOR 1.00 X 0 0 0 TUESDAE STAINBROOK DO MPH DIRECTOR 1.00 X 0 0 0 RENEE WILLIAMS ESQUIRE DIRECTOR 1.00 X 0 0 0 SUZANNA MASARTIS CHIEF EXECUTIVE OFFICER 40.00 X 140000 0 0 140000 0 0 1 0 0 0 0 99337 577610 676947 LIVER HERO FUND 541700 2350 2350 2350 19512 19512 6040 99337 15660 -9620 -9620 689189 2350 0 9892 1551 1551 140000 63000 21000 56000 299619 147422 52991 99206 22768 11131 5566 6071 13428 13428 15727 15727 225 225 12061 5484 6577 20815 10177 5087 5551 84692 78654 5928 110 100706 100706 2370 2370 FACILITY AND EQUIPMENT 49968 49968 COMPUTER & WEB DESIGN 28682 169 28513 DUES AND SUBSCRIPTIONS 5406 102 5304 798018 468589 162491 166938 486797 357282 349770 364529 10000 5995 12699 14925 32467 9982 891733 752713 19092 11955 32767 9713 51859 21668 X 805224 725050 34650 5995 839874 731045 891733 752713 -108829 0 X X 0 1 X 1 0 X 730745 536709 647523 590978 679297 3185252 730745 536709 647523 590978 679297 3185252 1304310 1880942 1474 4213 1561 15231 19512 41991 3227243 47185 0.58280 0.61970 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 OPERATING LEASE OBLIGATIONS 9713 9713 X 689189 0 689189 0 689189 798018 0 798018 0 798018 PART X, LINE 2: THE TEXT OF THE FOOTNOTE TO COMMUNITY LIVER ALLIANCE'S FINANCIAL STATEMENTS THAT REPORTS THE ORGANIZATION'S LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740) IS AS FOLLOWS: THE ORGANIZATION IS EXEMPT FROM INCOME TAX UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. HOWEVER, INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO THE ORGANIZATION'S TAX-EXEMPT PURPOSE MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS INCOME. IN ADDITION, THE ORGANIZATION HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER SECTION 501(C)(3). IN ADDITION, THE ORGANIZATION QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER SECTION 170(B)(1)(A) AS IT HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER SECTION 509(A)(2). INCOME TAX BENEFITS ARE RECOGNIZED FOR INCOME TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, ONLY WHEN IT IS DETERMINED THAT THE INCOME TAX POSITION WILL MORE-LIKELY-THAN-NOT BE SUSTAINED UPON EXAMINATION BY TAXING AUTHORITIES. THE ORGANIZATION HAS ANALYZED TAX POSITIONS TAKEN FOR FILING WITH THE INTERNAL REVENUE SERVICE. THE ORGANIZATION BELIEVES THAT INCOME TAX FILING POSITIONS WILL BE SUSTAINED UPON EXAMINATION AND DOES NOT ANTICIPATE ANY ADJUSTMENTS THAT WOULD RESULT IN A MATERIAL ADVERSE EFFECT ON THE ORGANIZATION'S FINANCIAL CONDITION, RESULTS OF OPERATIONS OR CASH FLOWS. ACCORDINGLY, THE ORGANIZATION HAS NOT RECORDED ANY RESERVES, OR RELATED ACCRUALS FOR INTEREST AND PENALTIES FOR UNCERTAIN INCOME TAX POSITIONS AT DECEMBER 31, 2025 AND 2024. THE ORGANIZATION'S POLICY IS TO CLASSIFY ANY INCOME TAX RELATED INTEREST AND PENALTIES TO INTEREST EXPENSE AND OTHER EXPENSES, RESPECTIVELY. THE ORGANIZATION IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIODS IN PROGRESS. FLOWER CAMPAIGN 46060 43687 2373 844 2212 AWARDS LUNCHEON (YMAD) 57189 55650 1539 1550 4162 4339 734 4 2128 2128 3065 -1246 105377 99337 6040 1550 4162 8248 1700 15660 -9620 FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT AND CERTAIN MEMBERS OF THE FINANCE COMMITTEE OF THE ORGANIZATION REVIEWED THE 990 PRIOR TO IT BEING FILED WITH THE IRS. THE 990 IS AVAILABLE TO THE BOARD UPON REQUEST AND WILL BE DISTRIBUTED TO THE BOARD AT THE NEXT BOARD MEETING FOLLOWING THE FILING OF THE 990. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS AN ANNUAL BOARD OF DIRECTORS CONFLICT OF INTEREST DOCUMENT THAT IS COLLECTED AND REVIEWED EACH YEAR. FORM 990, PART VI, SECTION B, LINE 15 THE CLA EXECUTIVE COMMITTEE DETERMINES THE CEO/EXECUTIVE DIRECTOR'S ANNUAL COMPENSATION BASED ON PERFORMANCE AND BUDGET CONSTRAINTS. THE CEO DETERMINES THE CLA STAFF COMPENSATION BASED ON LOCAL NONPROFIT COMPENSATION TRENDS, PERFORMANCE, EXPERIENCE AND BUDGET CONSTRAINTS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUREST. FORM 990 PAGE 12, PART XII, PART 2C NO CHANGES MADE FOR THE CURRENT YEAR.